Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TCEA1
REST API REST API
Homo sapiens
TCEA1 is differentially expressed in 263 experiments: 100 organism parts: cervix, heart, ... (98 more);, 166 disease states: normal, lung adenocarcinoma, ... (164 more);, 73 cell types 324 cell lines 30 compound treatments and 64 other conditions.
Synonyms TFIIS, SII, TCEA, TF2S, GTF2S
Orthologs tcea1 (Danio rerio)   TCEA1 (Gallus gallus)   Tcea1 (Mus musculus)   ENSCING00000007759 (Ciona intestinalis)   DST1 (Saccharomyces cerevisiae)   TfIIS (Drosophila melanogaster)   TCEA1_BOVIN (Bos taurus)   CG8117 (Drosophila melanogaster)   F1LV22_RAT (Rattus norvegicus)   Tcea1 (Rattus norvegicus)   tcea1 (Xenopus laevis)   TCEA1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, nucleotide-excision repair, protein binding, DNA repair, regulation of transcription, DNA-dependent, translation elongation factor activity, transcription, DNA-dependent, metal ion binding, nucleic acid binding, transcription from RNA polymerase II promoter, positive regulation of transcription from RNA polymerase II promoter, nucleus, nucleoplasm, regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, zinc ion binding, viral reproduction, transcription-coupled nucleotide-excision repair, erythrocyte differentiation, gene expression, positive regulation of viral transcription, regulation of transcription elongation, DNA-dependent, transcription elongation, DNA-dependent, transcription elongation from RNA polymerase II promoter
InterPro Term TFIIS_N, TFIIS/CRSP70_N_sub, TF_IIS, TFSII, TFS2M, TFIIS_cen_dom, Znf_TFIIS
UniProt Accession P23193, B7Z4S1, E5RFI1, E5RJ93, E5RIS7, E5RK46
Search EB-eye ENSG00000187735
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-1577, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, ... (36 experiments)

Factor Value U/D Experiments
LNCaP
2
E-GEOD-14464, E-GEOD-14990
MCF-7
2
E-GEOD-19639, E-GEOD-20081
Raji
2
E-MTAB-37, E-GEOD-96
HEL9217
1
E-MTAB-37
HCC78
1
E-MTAB-62
RPMI 8226
1
E-MEXP-921
318 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-13987, ... (38 experiments)

Factor Value U/D Experiments
hematopoietic progenitor cells
1
E-MEXP-70
M1 macrophage
1
E-GEOD-5099
hematopoietic stem cell
1
E-MEXP-1403
memory B cell
1
E-TABM-702
CD34+ progenitor cell
1
E-GEOD-96
adipose stem cells derived from adult human donor
1
E-GEOD-20033
67 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MTAB-680, E-MTAB-62, ... (53 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-MTAB-62
lung adenocarcinoma
1
3
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
embryonal rhabdomyosarcoma
2
E-MTAB-62, E-MEXP-121
acute lymphoblastic leukemia
2
E-MTAB-62, E-GEOD-96
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
160 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-6907, E-TABM-782, E-GEOD-5824, ... (20 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-5824, E-TABM-782, E-GEOD-412, E-TABM-868, E-GEOD-995, ... (9 experiments)
control
2
E-GEOD-3284, E-GEOD-995
AMP
1
E-MEXP-2285
epidermal growth factor
1
E-GEOD-6462
NaOH
1
E-MEXP-2590
granulocyte-colony stimulating factor
1
E-GEOD-7400
24 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-MEXP-2283, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-1751, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-TABM-763, E-GEOD-1923, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-12773, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-GEOD-5764, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-17636, E-MEXP-1403

Population
studied in E-GEOD-4922

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, ... (6 experiments)

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Vehicle
studied in E-GEOD-5258

Processing time: 0.442 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM